

Bridging the Funding Gap for Promising Cancer  
Therapeutics, Imaging Technologies, Interventional  
Devices, Diagnostics, and Prognostics

# SBIR Phase II Bridge Award

*The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are NCI's engines of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. For information on how to take your business innovations to the next level with funding opportunities available from the NCI SBIR & STTR Programs, visit [sbir.cancer.gov](http://sbir.cancer.gov). You can also contact an SBIR Program Director at [ncisbir@mail.nih.gov](mailto:ncisbir@mail.nih.gov) or 301-594-7709.*

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**National Institutes of Health**



**SBIR & STTR**

The Small Business Innovation Research Program

## NCI SBIR Program Announces the Phase II Bridge Award to Help Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization

The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program has announced \$10M in funding for up to 10 new awards in FY2011. The innovative funding opportunity, called the *SBIR Phase II Bridge Award*, is designed to support the next stage of development for previously funded NIH-wide SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, diagnostics, and prognostics. The purpose of this award is to address the funding gap known as the “Valley of Death” between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a product or service toward commercialization. To achieve this goal, the Bridge Award funding opportunity is specifically designed to incentivize partnerships between NIH’s SBIR Phase II awardees and third-party investors and/or strategic partners. **Competitive preference and funding priority will be given to applicants that demonstrate the ability to secure substantial independent third-party investor funds (i.e., third-party funds that equal or exceed the requested NCI funds).**

Budgets up to \$1 million in total costs per year and project periods up to three years (a total of \$3 million over three years) may be requested from the NCI. Development efforts may include preclinical R&D, which is needed for regulatory filings (e.g., IND or IDE), and/or clinical trials. An SBIR Phase II Bridge Award application must represent a continuation of the R&D efforts performed under a previously funded NIH SBIR Phase II award. Applications may be predicated on a previously funded SBIR Phase II grant or contract award regardless of the fiscal year in which the Phase I award began. In general, past Phase II projects should have ended within 24 months of the application receipt date. NCI reevaluates its programs and sets new funding levels each fiscal year.

### BENEFITS OF THE BRIDGE AWARD:

- Affords investors/strategic partners the opportunity to leverage up to \$3 million in NCI funding
- NCI takes no equity position in the companies
- All companies applying for the program have been vetted through the NIH peer review process
- NCI will be a partner in helping to advance projects into the clinic and towards commercialization

